


INTERNATIONAL DISCOVERY SERVICES & CONSULTING

Pharmacum Nuntius:

October 2013, Volume II, Issue III

Whether on your morning commute or between meetings, here are a few interesting articles for your reading pleasure. They cover medical foods, stem cells, and the latest marketed drug for mycosis fungoides. I hope you enjoy them.

Mark Creswell, CEO



Medical Foods: A Review on History, FDA Enforcement, the Future

In her recent article on Medical Foods (MFs), Emalee Murphy writes about the history of MFs including its formal definition in the 1988 Orphan Drug Amendments. The article further describes the FDA enforcement around MFs and discusses the future of a \$2 Billion US industry as the USA population ages and “more people are in hospitals, nursing homes or lose the ability to eat or metabolize food normally...”

[Click here for the article.](#)




IDSC White Paper on Nutraceuticals:

To guide our clients in understanding and navigating the ever growing area of nutraceuticals, our director Dr. Lauren Constantini has written an article comparing and contrasting the different products that fall under the broad category of nutraceuticals such as: medical foods, homeopathics, dietary supplements, and functional foods. Lauren’s article digs deeper into the arena of medical foods including their criteria and the advantages and disadvantages of the medical food opportunity. [Click here to view the article.](#)



Draft Guidance for the Industry: FDA frequently asked questions about Medical Foods were recently (08/13) revised and can be found on the FDA website: [Click here to view the page.](#)



Three Stem Cell Teasers:

Patents may supply their own treatment: [Click here to view the article.](#)

Drug limits CMV infection in transplant patients: [Click here to view the article.](#)

'Stem cells created in living mice' but we still have a long way from a cure: Read the [Nature news article...](#)



New drug approved for Mycosis Fungoides:

[Ceptaris Therapeutic's](#) new mycosis fungoides drug [Valchlor® \(mechlorethamine\)](#) Topical Gel has been approved for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. The approval is for patients who have received prior skin-directed therapy.



For more information about IDSC:

Click on our website: WWW.IDSCBIOTECHNETWORK.COM



A Spotlight on IDSC's Director...Lauren Costantini: Nutraceuticals... Medical Foods, Dietary Supplements, and Functional Foods

Lauren Costantini is an advisor to emerging life science and medical technology companies. She has 20+ years developing therapeutics for several indications, with an emphasis on neurodegenerative diseases. Her experience includes leading products from research through clinical, regulatory, and commercialization stages. She also plays a key role connecting her early-stage companies with potential partners, venture capital, and angel investors, as well as directing due diligence for in- and out-licensing activities. She is currently Vice President of Therapeutics and Device Development for CID4, and holds board seats in several companies and non-profits. Previously she was Vice President at Accera where her team developed and launched an Alzheimer's therapeutic, she was on faculty at Harvard Medical School, and was voted 'Business Advisor of the Year' 2011 by U Colorado TTO.

FROM HIT TO THE CLINIC: IDSC IS YOUR DRUG DISCOVERY AND DEVELOPMENT PARTNER

www.idscbiotechnetwork.com